Gene study aims to personalize diabetes treatment
NCT ID NCT01762046
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at how inherited gene variants influence the body's response to two common type 2 diabetes medications, metformin and glipizide. Over 1,000 participants took each drug and had their glucose and insulin levels measured. The goal was to understand why some people respond better than others, which could lead to more personalized treatment in the future.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Metformin and glipizide
- What this could lead to
- If successful, this could help doctors personalize diabetes treatment based on a person's genes.
- What could go wrong
- This is a completed early-phase study focused on understanding genetics, not testing a new treatment. Results may not lead to immediate changes in care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
1,033 people
The number who actually took part.
- Started
-
Jan 2008
- Finished
-
Dec 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 85 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Male or non-pregnant female \> 18 years of age * Investigators will target preferentially people at risk of diabetes or requiring diabetes meds * The first tier of risk will be illustrated by one of the following variables (e.g. established type 2 diabetes on diet therapy alone, elevated random glucose in electronic medical record, PCOS, metabolic syndrome, obesity, history of gestational diabetes, etc.) * The second tier of risk will be illustrated by other features that correlate with diabetes risk, such as a history of hypertension or dyslipidemia * Otherwise healthy subjects may also be candidates for the study. * Able and willing to give consent relevant to genetic investigation Exclusion Criteria: * Pregnant, nursing or at risk of becoming pregnant * Currently taking any medications for the treatment of diabetes * Currently on metformin for any other indication (e.g. PCOS) * Onset of diabetes in a family member before age 25, with autosomal transmission of diabetes across three generations * History of liver or kidney disease * Known severe allergic reactions to sulfonamides * History of porphyria * Documented estimated glomerular filtration rate (GFR) \< 60 ml/min/1.73 m2, based on the most recent serum creatinine measurement available in the electronic medical record, and calculated by the Modification of Diet in Renal Disease equation (49) available at http://www.nephron.com/cgi-bin/MDRD\_GFR.cgi * Currently taking medications known to affect glycemic parameters, such as glucocorticoids, growth hormone or fluoroquinolones * Planned radiologic or angiographic study requiring contrast within one week of completion of this study * Established coronary artery disease (CAD), defined as: * History of myocardial infarction. * History of revascularization (coronary artery bypass grafting, percutaneous coronary intervention (e.g. stenting or balloon angioplasty). * Evidence of ischemia on cardiac stress test. * Enrolled in any other interventional study at time of screening through completion of study protocol * History of bariatric surgery * History of seizures * History of stroke/CVA
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Diabetes mellitus type 2 are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02116, United States
-
Joslin Diabetes Center
Boston, Massachusetts, 02116, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a nurse and a neighbor help tame chronic disease?
- Which SGLT2 inhibitor wins? trial pits empagliflozin against dapagliflozin
- Can a vegan diet shield police officers from heart disease?
- Can a health coach in your patient portal help you lose weight?
- Common antibiotic may boost diabetes control
- Can continuous glucose monitors safely tighten hospital blood sugar control?